UBS raised the firm’s price target on Regeneron (REGN) to $660 from $595 and keeps a Neutral rating on the shares. The firm updated its model following the Q3 earnings report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron’s Aflibercept Study Completion: Implications for Investors
- Insider Moves: Blackstone, Regeneron, Schwab, Celestica, Corning
- Regeneron’s New Study Targets Improved Outcomes in Multiple Myeloma
- Regeneron’s Aflibercept Study Sheds Light on Retinal Vasculitis Incidence
- Regeneron price target raised to $708 from $704 at RBC Capital